-4.5 | | Gm7538 | 'synovial sarcoma' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
-4.4 | | Gm7538 | 'clear cell sarcoma; TATCre' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
-4.3 | | Gm7538 | 'osteosarcoma' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
-3.4 | | Gm7538 | 'tamoxifen induction at 2 months, wait 6 months' vs 'no tamoxifen induction' in 'basal cell of prostate epithelium; CK5-CreERT2 transgenic line' | cell type, genotype, growth condition | Transcription profiling by high throughput sequencing of PIN/tumor lesions from basal or luminal origins at time points at which mice displayed similar histopathological phenotypes |
-3.4 | | Gm7538 | 'clear cell sarcoma; Rosa26CreER' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
-2.9 | | Gm7538 | 'tamoxifen induction at 2 months, wait 3 months' vs 'no tamoxifen induction' in 'luminal cell of prostate epithelium; Nkx3.1-CreERT2 targeted allele' | cell type, genotype, growth condition | Transcription profiling by high throughput sequencing of PIN/tumor lesions from basal or luminal origins at time points at which mice displayed similar histopathological phenotypes |
-2.5 | | Gm7538 | 'tamoxifen induction at 2 months, wait 1 months' vs 'no tamoxifen induction' in 'luminal cell of prostate epithelium; Nkx3.1-CreERT2 targeted allele' | cell type, genotype, growth condition | Transcription profiling by high throughput sequencing of PIN/tumor lesions from basal or luminal origins at time points at which mice displayed similar histopathological phenotypes |
-1.8 | | Gm7538 | 'tamoxifen induction at 2 months, wait 3 months' vs 'no tamoxifen induction' in 'basal cell of prostate epithelium; CK5-CreERT2 transgenic line' | cell type, genotype, growth condition | Transcription profiling by high throughput sequencing of PIN/tumor lesions from basal or luminal origins at time points at which mice displayed similar histopathological phenotypes |